How can we help?
Avoid blind spots in your market. Get the insights you need to accelerate innovation.
We made a brief appearance at ASHG this year. Given the time constraint, we unfortunately did not get a chance to attend any sessions; however, walking through the exhibit hall and talking to friends and attendees, here are a couple of highlights this year (outside of the Illumina party).
10x Genomics Workshop hosted a “standing room only” workshop entitled: “Biology at True Resolution: Enabling a comprehensive view of genomics.”
The company provided a review of their current 10x portfolio of products and of their newly introduced solutions. The 10X Genomics portfolio now consists of:
The workshop also highlighted two customer talks. Molly Gasperini (University of Washington) spoke about her work using 10X for highly multiplexed functional genomics with Single Cell Gene Expression and CRISPR screening to show that known enhancer marks are quantitatively predictive of crisprQTLs. Jimmie Ye (UCSF) spoke about population scaled single cell experiments for the understanding of healthy humans and patients with autoimmune disease like Lupus.
We also talked with the Mission Bio team, who continues to lead the charge in hematology with its 19-gene AML and 47-gene myeloid panels. The company focuses on clinically actionable genes at the DNA level, with customers primarily focusing on MRD and disease clonal evolution. As a result, the company reports significant penetration in the ~70 leading cancer centers, and good penetration in pharma (on the Heme side), with customers having having sequenced over 2M cells in aggregate since launch. Mission Bio intends to move into solid tumor profiling next year, and place an increase emphasis on the gene editing space (CAR-T angle). This week they also announced joining the NIST Genome Editing Consortium, as the only single-cell DNA platform to provide quality control for CRISPR gene editing.
Finally, we also had the chance to talk with the Dolomite Bio team. The company is emphasizing the open / flexible nature of its recently launched, cost effective Nadia platform. Customers reportedly have been using the instrument for a broad range of single cell and nuclei applications in oncology, plant biology, neuroscience, and basic cell biology research. Dolomite Bio expects an installed base of ~40 Nadia instruments by the end of 2018.
Last week, Amgen invested £50M in ONT, valuing the company at £1.5B (~$2.0B). We attended the workshop on Thursday evening, and most notably Clive’s talk. The biggest announcement was undoubtedly the developer access to the R10 pore (and associated Medaka software) by the end of the month. The pore already achieves Q40 accuracy (99.99%, polished from base call) at 75x coverage (vs. Q34 for R9.4 at its best from polished from signal) in-house; we look forward to results in the field. This improvement in accuracy is driven by the new pore structure that has 2 “reading heads” which enables to better decode homopolymers that are 4+ in length.
The company shared additional information, including:
We estimate that Oxford Nanopore revenues will almost triple in 2018, largely driven by PromethION adoption.
Disclaimer: Companies listed above may be DeciBio clients and/or customers.